a, Total number of validated tier 1–3 somatic SNVs in t-AML (n=22), de novo AML (n=49), and s-AML (n=8). The mean ages of the t-AML, de novo AML, and s-AML cohorts were 55.7, 51, and 54.6 years respectively. b, Number of validated tier 1 somatic SNVs. c, Number of validated tier 1 small insertions/deletions (indels). d, Percentage of tier 1–3 somatic SNVs that are transversions. e, Mutational spectrum for all validated tier 1–3 somatic SNVs. f, Number of distinct clones per sample inferred from the identification of discrete clusters of mutations with distinct variant allele frequencies. g, Percentage of cases of t-AML (n=52) or de novo AML (n=199) harboring non-synonymous mutations of the indicated gene. h, Percentage of cases of t-MDS (n=59) or de novo MDS (n=150) harboring non-synonymous mutations of the indicated gene. ABC Fm: ABC family genes; NA: not available; s-AML: AML following MDS. +P<0.05 by one-way Anova. *P<0.05 by Fisher's Exact test. Data represent the mean ± SD.